Table 4.

Proportion Quit × Time (7-Day Point Prevalence)

	Week postquit day
Condition	1	2	4	6	8a	12	16	24	32	MPPb
Missing data = smoking (n = 989)
Placebo	.39	.36	.29	.27	.26	.25	.26	.19	.18	.10
30 mg	.43	.41	.38*	.34	.32	.27	.25	.20	.16	.10
60 mg	.45	.39	.38*	.35	.33	.29	.23	.19	.15	.10
Incomplete treatment phase datac
Placebo	.25	.18	.09	.04
30 mg	.29	.24	.18	.19
60 mg	.29	.23	.18	.11
Complete treatment phase datad
Placebo	.54	.55	.46	.45	.44
30 mg	.59	.60	.60*	.58*	.54*
60 mg	.67*	.62	63*	.64*	.62*
Averaged resultse
Placebo	.45	.46	.39	.40	.44
30 mg	.49	.50	.51*	.53*	.54*
60 mg	.53	.50	.51*	.57*	.62*
End-of-treatment abstainersf
Placebo						.92	.96	.90	.91
30 mg						.83	.84*	.91	.83
60 mg						.85	.80*	.81	.86

^aEnd of treatment.

^bMultiple point prevalence (MPP) denoting verified abstinence at the 26-week follow-up and at all preceding intervals.

^cns = 289, 222, 163, and 80, respectively.

^dns = 570, 570, 568, 558, and 570, respectively.

^ens = 859, 792, 731, 638, and 570, respectively.

^fns = 281, 256, 210, and 180, respectively.

^*Different than placebo at p ≤ .05 by chi-square test.